Humabs BioMed SA - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Humabs BioMed SA - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Humabs BioMed SA - Product Pipeline Review - 2015', provides an overview of the Humabs BioMed SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Humabs BioMed SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Humabs BioMed SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Humabs BioMed SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Humabs BioMed SA's pipeline products

Reason to Buy

- Evaluate Humabs BioMed SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Humabs BioMed SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Humabs BioMed SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Humabs BioMed SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Humabs BioMed SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Humabs BioMed SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Humabs BioMed SA Snapshot 6
Humabs BioMed SA Overview 6
Key Information 6
Key Facts 6
Humabs BioMed SA - Research and Development Overview 7
Key Therapeutic Areas 7
Humabs BioMed SA - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Humabs BioMed SA - Pipeline Products Glance 14
Humabs BioMed SA - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Humabs BioMed SA - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Humabs BioMed SA - Drug Profiles 18
Monoclonal Antibody for HCMV Infections 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
FI-6 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Monoclonal Antibody for Bacterial Infections 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibody for Dengue 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibody for Ebola Virus Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibody for HBV Infections 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody for Hepatitis C Infection 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Monoclonal Antibody for Influenza B Infections 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibody for MERS and SARS 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibody for Rabies 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Monoclonal Antibody for RSV Infections 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibody for Staphylococcus Aureus Infections 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MPE-8 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NVB-71.4 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Monoclonal Antibody for Herpes Simplex Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Monoclonal Antibody for JCV and BKV Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody for Solid Tumor 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody for Undisclosed Indication 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Monoclonal Antibody to Inhibit GM-CSF for Immunological Disorders 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Humabs BioMed SA - Pipeline Analysis 37
Humabs BioMed SA - Pipeline Products by Target 37
Humabs BioMed SA - Pipeline Products by Molecule Type 38
Humabs BioMed SA - Pipeline Products by Mechanism of Action 39
Humabs BioMed SA - Locations And Subsidiaries 40
Head Office 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 41
Disclaimer 42

List of Tables

Humabs BioMed SA, Key Information 6
Humabs BioMed SA, Key Facts 6
Humabs BioMed SA - Pipeline by Indication, 2015 9
Humabs BioMed SA - Pipeline by Stage of Development, 2015 10
Humabs BioMed SA - Monotherapy Products in Pipeline, 2015 11
Humabs BioMed SA - Out-Licensed Products in Pipeline, 2015 12
Humabs BioMed SA - Out-Licensed Products/ Combination Treatment Modalities, 2015 13
Humabs BioMed SA - Phase II, 2015 14
Humabs BioMed SA - Phase I, 2015 15
Humabs BioMed SA - Preclinical, 2015 16
Humabs BioMed SA - Discovery, 2015 17
Humabs BioMed SA - Pipeline by Target, 2015 37
Humabs BioMed SA - Pipeline by Molecule Type, 2015 38
Humabs BioMed SA - Pipeline Products by Mechanism of Action, 2015 39